Opin vísindi
→
Fletta eftir höfundi

Fletta eftir höfundi "Gudbjornsson, Bjorn"

Atriði 1-11 af 11

Active conventional treatment and three different biological treatments in early rheumatoid arthritis : Phase IV investigator initiated, randomised, observer blinded clinical trial

Hetland, Merete Lund; Haavardsholm, Espen A.; Rudin, Anna; Nordström, Dan; Nurmohamed, Michael; Gudbjornsson, Bjorn; Lampa, Jon; Hørslev-Petersen, Kim; Uhlig, Till; Grondal, Gerdur; Østergaard, Mikkel; Heiberg, Marte S.; Twisk, Jos; Lend, Kristina; Krabbe, Simon; Hyldstrup, Lise Hejl; Lindqvist, Joakim; Hultgård Ekwall, Anna Karin; Grøn, Kathrine Lederballe; Kapetanovic, Meliha; Faustini, Francesca; Tuompo, Riitta; Lorenzen, Tove; Cagnotto, Giovanni; Baecklund, Eva; Hendricks, Oliver; Vedder, Daisy; Sokka-Isler, Tuulikki; Husmark, Tomas; Ljoså, Maud Kristine Aga; Brodin, Eli; Ellingsen, Torkell; Söderbergh, Annika; Rizk, Milad; Olsson, Åsa Reckner; Larsson, Per; Uhrenholt, Line; Just, Søren Andreas; Stevens, David John; Laurberg, Trine Bay; Bakland, Gunnstein; Olsen, Inge C.; Van Vollenhoven, Ronald (2020-12-02)

AbstractObjective To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active conventional treatment in patients with early rheumatoid arthritis. Design Investigator initiated, randomised, open ...
A Clinical Decision Support System for the Diagnosis, Fracture Risks and Treatment of Osteoporosis

Halldórsson, Bjarni; Bjornsson, Aron Hjalti; Guðmundsson, Haukur Týr; Birgisson, Elvar Orn; Ludviksson, Bjorn; Gudbjornsson, Bjorn (Hindawi Limited, 2015)

Expanding medical knowledge increases the potential risk of medical errors in clinical practice. We present, OPAD, a clinical decision support systemin the field of the medical care of osteoporosis. We utilize clinical information from international ...
Clinical decision support system for the management of osteoporosis compared to NOGG guidelines and an osteology specialist: a validation pilot study

Guðmundsson, Haukur Týr; Hansen, Karen E.; Halldórsson, Bjarni; Ludviksson, Bjorn; Gudbjornsson, Bjorn (Springer Science and Business Media LLC, 2019-02-01)

Background: Although osteoporosis is an easily diagnosed and treatable condition, many individuals remain untreated. Clinical decision support systems might increase appropriate treatment of osteoporosis. We designed the Osteoporosis Advisor (OPAD), a ...
Correction to : Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration (Rheumatology (Oxford, England) (2022) 61 11 (4286-4296))

Delcoigne, Bénédicte; Provan, Sella Aarrestad; Hammer, Hilde Berner; Di Giuseppe, Daniela; Frisell, Thomas; Glintborg, Bente; Grondal, Gerdur; Gudbjornsson, Bjorn; Hetland, Merete Lund; Michelsen, Brigitte; Nordström, Dan; Relas, Heikki; Askling, Johan (2022-03-25)
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel (BMJ, 2020-09-01)

OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) ...
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

Chatzidionysiou, Katerina; Delcoigne, Bénédicte; Frisell, Thomas; Hetland, Merete L; Glintborg, Bente; dreyer, lene; Cordtz, René; Zobbe, Kristian; Nordström, Dan; Trokovic, Nina; Aaltonen, Kalle; Provan, Sella Aarrestad; Gröndal, Gerður; Gudbjornsson, Bjorn; Askling, Johan (BMJ, 2020-09-08)

[No abstract available]
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry

Gudbjornsson, Bjorn; Geirsson, Árni J.; Krogh, Niels Steen (Dove Medical Press Ltd., 2018-05)

Objective: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA). Methods: Biologically naïve PsA ...
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible

Palsson, Olafur; Löve, Þorvarður Jón; Gunnarsdóttir, Anna Ingibjörg; Gunnarsson, Pétur Sigurður; Rúnarsdóttir, Eydís Erla; Krogh, Niels Steen; Gudbjornsson, Bjorn (BMJ, 2019-07)

Objectives To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) ...
Rare coding variants in NOX4 link high ROS levels to psoriatic arthritis mutilans

Wang, Sailan; Nikamo, Pernilla; Laasonen, Leena; Gudbjornsson, Bjorn; Ejstrup, Leif; Iversen, Lars; Lindqvist, Ulla; Alm, Jessica J.; Eisfeldt, Jesper; Zheng, Xiaowei; Catrina, Sergiu Bogdan; Taylan, Fulya; Vaz, Raquel; Ståhle, Mona; Tapia-Paez, Isabel (2024-02-20)

Psoriatic arthritis mutilans (PAM) is the rarest and most severe form of psoriatic arthritis, characterized by erosions of the small joints and osteolysis leading to joint disruption. Despite its severity, the underlying mechanisms are unknown, and no ...
Sarcoidosis in Iceland : A nationwide study of epidemiology, clinical picture and environmental exposure

Haraldsdóttir, Sigríður Ólína; Jonasson, Jon Gunnlaugur; Jorundsdottir, Kristin Bara; Hannesson, Haraldur Jon; Gislason, Thorarinn; Gudbjornsson, Bjorn (2021-10-01)

Background This nationwide study aimed to elucidate the incidence and clinical characteristics of tissueverified sarcoidosis in Iceland. A secondary aim was to analyse sex differences and identify possible environmental factors contributing to the ...
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis

Lindström, Ulf; Glintborg, Bente; Di Giuseppe, Daniela; Nordström, Dan; Aarrestad Provan, Sella; Gudbjornsson, Bjorn; Askling, Johan; Hetland, Merete Lund; Aaltonen, Kalle; Krogh, Niels Steen; Geirsson, Árni J.; Jacobsson, Lennart (BMJ, 2019-10)

Objective Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naïve patients with spondyloarthritis (SpA) are lacking. The objectives were to compare ...

Atriði 1-11 af 11

Leita

Fletta

Opin vísindi
- Efnisflokkar
- Höfundar
- Titlar
- Efnisorð
- Deildir
- Svið
- DOI
- Titill tímarits

Fletta eftir höfundi "Gudbjornsson, Bjorn"

Fletta eftir höfundi "Gudbjornsson, Bjorn"

Leita

Fletta

Opin vísindi

Um vefinn

Reikningurinn minn